These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 20215558)

  • 1. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
    Dancey JE; Dobbin KK; Groshen S; Jessup JM; Hruszkewycz AH; Koehler M; Parchment R; Ratain MJ; Shankar LK; Stadler WM; True LD; Gravell A; Grever MR;
    Clin Cancer Res; 2010 Mar; 16(6):1745-55. PubMed ID: 20215558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
    LoRusso PM; Boerner SA; Seymour L
    Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
    Seymour L; Ivy SP; Sargent D; Spriggs D; Baker L; Rubinstein L; Ratain MJ; Le Blanc M; Stewart D; Crowley J; Groshen S; Humphrey JS; West P; Berry D
    Clin Cancer Res; 2010 Mar; 16(6):1764-9. PubMed ID: 20215557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel designs and end points for phase II clinical trials.
    Adjei AA; Christian M; Ivy P
    Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.
    Ivy SP; Siu LL; Garrett-Mayer E; Rubinstein L
    Clin Cancer Res; 2010 Mar; 16(6):1726-36. PubMed ID: 20215542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The investigational drug steering committee.
    Ratain MJ
    Clin Adv Hematol Oncol; 2007 Oct; 5(10):779-80. PubMed ID: 17998895
    [No Abstract]   [Full Text] [Related]  

  • 10. New science-based endpoints to accelerate oncology drug development.
    Kelloff GJ; Sigman CC
    Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GCP data quality for early clinical development.
    Rock EP; Molloy VJ; Humphrey JS
    Clin Cancer Res; 2010 Mar; 16(6):1756-63. PubMed ID: 20215550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
    Paller CJ; Bradbury PA; Ivy SP; Seymour L; LoRusso PM; Baker L; Rubinstein L; Huang E; Collyar D; Groshen S; Reeves S; Ellis LM; Sargent DJ; Rosner GL; LeBlanc ML; Ratain MJ
    Clin Cancer Res; 2014 Aug; 20(16):4210-7. PubMed ID: 25125258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigational trials of anticancer drugs: establishing safeguards for experimentation.
    Chabner BA; Wittes R; Hoth D; Hubbard S
    Public Health Rep; 1984; 99(4):355-60. PubMed ID: 6431482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide.
    Minig L; Trimble EL; Birrer MJ; Kim KY; Takebe N; Abrams JS
    Gynecol Oncol; 2010 Feb; 116(2):177-80. PubMed ID: 19889449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.
    Christian MC; Pluda JM; Ho PT; Arbuck SG; Murgo AJ; Sausville EA
    Semin Oncol; 1997 Apr; 24(2):219-40. PubMed ID: 9129691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical development of atypical antipsychotics: research design and evaluation. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():10-6. PubMed ID: 9766614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.